NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

BCDA

BioCardia Inc

May 23 • 02:27PM ET

1.93

Dollar change +0.03
Percentage change 1.58	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP BLUE NTLA CLLS QURE EDIT SGMO FATE BOLD CLRB

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.58	Insider Own	27.69%	Shs Outstand	4.68M	Perf Week	-20.90%
Market Cap	10.00M	Forward P/E	-	EPS next Y	-1.00	Insider Trans	32.07%	Shs Float	3.74M	Perf Month	6.34%
Income	-8.39M	PEG	-	EPS next Q	-0.50	Inst Own	4.75%	Short Float	3.66%	Perf Quarter	-10.23%
Sales	0.00M	P/S	-	EPS this Y	58.62%	Inst Trans	65.95%	Short Ratio	1.64	Perf Half Y	-4.93%
Book/sh	-0.32	P/B	-	EPS next Y	16.67%	ROA	-346.38%	Short Interest	0.14M	Perf Year	-68.31%
Cash/sh	0.18	P/C	10.52	EPS next 5Y	31.06%	ROE	-737.89%	52W Range	1.62 - 5.69	Perf YTD	-11.47%
Dividend Est.	-	P/FCF	-	EPS past 5Y	40.58%	ROI	-	52W High	-66.08%	Beta	0.83
Dividend TTM	-	Quick Ratio	0.36	Sales past 5Y	80.21%	Gross Margin	-14333.33%	52W Low	18.77%	ATR (14)	0.26
Dividend Ex-Date	-	Current Ratio	0.36	EPS Y/Y TTM	63.06%	Oper. Margin	-281733.33%	RSI (14)	39.05	Volatility	5.85% 10.16%
Employees	20	Debt/Eq	-	Sales Y/Y TTM	-99.36%	Profit Margin	-279700.00%	Recom	1.00	Target Price	6.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	56.76%	Payout	-	Rel Volume	0.38	Prev Close	1.90
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-100.00%	Earnings	May 14 AMC	Avg Volume	83.66K	Price	1.93
SMA20	-23.41%	SMA50	-17.68%	SMA200	-20.76%	Trades		Volume	24,809	Change	1.58%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-16-21	Downgrade	Dawson James	Buy → Neutral

May-21-25 08:30AM	BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025 (GlobeNewswire)
May-15-25 03:16AM	BioCardia Inc (BCDA) Q1 2025 Earnings Call Highlights: Progress in Cardiac Cell Therapy Amid ... (GuruFocus.com) -16.25%
May-14-25 04:05PM	BioCardia Reports First Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
May-09-25 04:28PM	BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025 (GlobeNewswire)
May-06-25 08:00AM	BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study (GlobeNewswire)
11:03AM	Loading…
May-02-25 11:03AM	First subject enrolled in BioCardias Phase III heart failure therapy trial (Clinical Trials Arena) -5.96%
May-01-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks) -9.24%
09:00AM	BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company's Lead Cell Therapy for Treatment of Heart Failure (GlobeNewswire)
Apr-16-25 05:45AM	DSMB recommends continuation of BioCardias cell therapy trial for heart failure (Clinical Trials Arena) -6.83%
Apr-15-25 08:30AM	BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial (GlobeNewswire)
Apr-14-25 06:52AM	Emory begins enrolment for BioCardias trial of ischemic heart failure therapy (Clinical Trials Arena)
Apr-11-25 09:15AM	BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study (GlobeNewswire)
Apr-01-25 08:24AM	Q4 2024 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents) -15.75%
03:03AM	BioCardia Inc (BCDA) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and Promising ... (GuruFocus.com)
Mar-31-25 11:32PM	ACC 25: Biocardias CardiAMP trial fails but cell therapy potential remains (Clinical Trials Arena) -9.29%
11:30PM	Loading…
11:30PM	BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript (Seeking Alpha)
01:39PM	BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today (GlobeNewswire)
08:00AM	Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years (GlobeNewswire)
Mar-26-25 04:30PM	BioCardia Reports 2024 Business Highlights and Financial Results (GlobeNewswire) +5.10%
Mar-25-25 09:05AM	What To Expect From BioCardia Inc (BCDA) Q4 2024 Earnings (GuruFocus.com)
Mar-21-25 08:30AM	BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025 (GlobeNewswire) +7.69%
Mar-10-25 09:15AM	BioCardia Announces Japanese Patent for Helix Biotherapeutic Delivery System (GlobeNewswire)
Feb-27-25 09:15AM	BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions (GlobeNewswire)
Feb-13-25 08:30AM	BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) (GlobeNewswire)
Jan-31-25 07:16AM	BioCardia upgraded to Buy from Neutral at Alliance Global Partners (TipRanks) +6.47%
Jan-27-25 09:15AM	BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions (GlobeNewswire)
Dec-17-24 07:00AM	BioCardia Announces Commercial Availability of Morph DNA Steerable Introducer Product Family (GlobeNewswire)
Dec-04-24 08:30AM	BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure (GlobeNewswire)
Nov-14-24 02:13AM	BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ... (GuruFocus.com) -14.26%
Nov-13-24 04:05PM	BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
07:00AM	Loading…
Nov-06-24 07:00AM	BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024 (GlobeNewswire)
Oct-28-24 09:00AM	BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure (GlobeNewswire) +8.68%
Oct-09-24 06:19PM	BioCardia Inc (BCDA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Sep-18-24 08:30AM	BioCardia Regains Full Compliance with Nasdaq Listing Requirements (GlobeNewswire) +10.39%
Sep-09-24 04:05PM	BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +6.17% +6.64%
Aug-30-24 08:00AM	BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -24.13%
Aug-29-24 08:30AM	BioCardia Announces FDA Market Clearance of Morph DNA Steerable Introducer Product Family (GlobeNewswire) +82.73%
Aug-21-24 07:00AM	FDA Approves CardiAMP Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment (GlobeNewswire) -12.91%
Aug-13-24 04:30PM	BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Aug-07-24 07:00AM	BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024 (GlobeNewswire) +5.95%
Jul-30-24 07:00AM	BioCardia Submits for FDA Approval of Morph DNA Steerable Introducer Product Family (GlobeNewswire)
Jul-25-24 07:00AM	Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure (GlobeNewswire)
Jul-17-24 07:00AM	BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application (GlobeNewswire)
Jul-08-24 07:00AM	CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes for the Treatment of Acute Myocardial Infarction (GlobeNewswire)
Jun-10-24 07:32AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -7.80%
Jun-07-24 07:00AM	BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach (GlobeNewswire) -14.78%
Jun-04-24 07:52AM	BCDA Stock Earnings: BioCardia Misses EPS, Misses Revenue for Q2 2023 (InvestorPlace)
May-21-24 05:00PM	BioCardia Announces Reverse Stock Split (GlobeNewswire) -23.82%
May-15-24 03:08AM	BioCardia Inc (BCDA) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress Amid ... (GuruFocus.com)
May-14-24 08:56PM	BCDA Stock Earnings: BioCardia Reported Results for Q1 2024 (InvestorPlace)
04:02PM	BioCardia Reports First Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
May-09-24 07:00AM	BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024 (GlobeNewswire)
May-01-24 07:00AM	BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes (GlobeNewswire)
Apr-25-24 09:00AM	BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort (GlobeNewswire)
Apr-02-24 05:41PM	Insiders Are Buying These 11 Penny Stocks (Insider Monkey)
Apr-01-24 02:30PM	BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-28-24 05:58AM	Q4 2023 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-27-24 08:53PM	BCDA Stock Earnings: BioCardia Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:00PM	BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results (GlobeNewswire)
Mar-20-24 07:00AM	BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024 (GlobeNewswire)
Mar-13-24 07:00AM	BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership (GlobeNewswire)
Mar-12-24 07:00AM	BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study (GlobeNewswire) -9.49%
Mar-04-24 09:27AM	BioCardia rejigs phase 3 heart failure data to find a path forward for cell therapy (FierceBiotech.com) -21.51%
08:00AM	BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure (GlobeNewswire)
Feb-08-24 07:00AM	BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA (GlobeNewswire) -10.34%
Jan-31-24 07:00AM	BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference (GlobeNewswire) -5.66%
Jan-03-24 07:00AM	BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders (GlobeNewswire)
Dec-19-23 07:00AM	BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction (GlobeNewswire)
Dec-18-23 07:16AM	BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes (GlobeNewswire) +8.32%
Nov-29-23 07:00AM	BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval (GlobeNewswire)
Nov-16-23 12:56PM	BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules (GlobeNewswire) -15.27%
Nov-15-23 11:04AM	BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study (Zacks) -11.68%
Nov-14-23 07:15AM	BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure (GlobeNewswire) +168.17%
Nov-09-23 12:48PM	BioCardia, Inc. (NASDAQ:BCDA) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.75%
06:59AM	Q3 2023 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-08-23 05:52PM	BioCardia Inc (BCDA) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com) +6.10%
05:50PM	BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:11PM	BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results (GlobeNewswire)
Nov-01-23 05:04PM	BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023 (GlobeNewswire)
Oct-12-23 11:08AM	BioCardia (BCDA) Up on Plans for Second Heart Failure Study (Zacks) -13.88%
Oct-11-23 06:00AM	BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II (GlobeNewswire) +28.30%
Sep-06-23 10:31AM	BioCardia (BCDA) Dips 26% on Flunking Heart Failure Study (Zacks) -12.59%
07:15AM	BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs (GlobeNewswire)
Sep-05-23 07:15AM	BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial (GlobeNewswire) -25.54%
Aug-11-23 09:29AM	BioCardia, Inc. (NASDAQ:BCDA) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-09-23 06:05PM	BioCardia, Inc. (BCDA) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +6.28%
04:05PM	BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results (GlobeNewswire)
Aug-02-23 07:00AM	BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023 (GlobeNewswire)
Jul-24-23 07:00AM	BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected (GlobeNewswire) -44.70%
Jul-10-23 08:11AM	Those who invested in BioCardia (NASDAQ:BCDA) a year ago are up 86% (Simply Wall St.)
Jul-05-23 07:00AM	BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure to Japans Pharmaceutical Medical Device Agency (GlobeNewswire)
Jun-20-23 05:14PM	BioCardia Announces FDA Completes Review of Proposed Adaptive Statistical Analysis Design for Ongoing CardiAMP Cell Therapy in Heart Failure Pivotal Study (GlobeNewswire) +6.41% +12.45%
Jun-08-23 07:00AM	BioCardia Announces Helix Biotherapeutic Delivery Patent Issuance in Japan (GlobeNewswire) +6.53%
May-28-23 08:08AM	Joseph Daly Spends US$177k Buying BioCardia Shares \ (Simply Wall St.)
May-23-23 07:00AM	BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study (GlobeNewswire)
May-12-23 06:06AM	BioCardia First Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
May-10-23 05:45PM	BioCardia, Inc. (BCDA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	BioCardia Reports First Quarter 2023 Business Highlights and Financial Results (GlobeNewswire)
May-09-23 07:00AM	BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications (GlobeNewswire)
May-03-23 08:00PM	BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023 (GlobeNewswire)

BioCardia, Inc. is a clinical-stage biotherapeutic company, which engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its pipeline includes CardiAMP, CardiALLO, PulmALLO, Helix Biotherapeutic Delivery System, and Morph DNA and Avance Steerable Introducers. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Altman Peter	President and CEO	May 20 '25	Buy	2.08	1,600	3,328	140,966	May 22 06:45 PM
Altman Peter	President and CEO	May 22 '25	Buy	1.89	700	1,323	141,666	May 22 06:45 PM
Altman Peter	President and CEO	May 16 '25	Buy	2.43	300	730	139,366	May 16 05:31 PM
Altman Peter	President and CEO	May 14 '25	Buy	2.99	100	299	139,066	May 16 05:31 PM
KRASNO RICHARD M	Director	Apr 23 '25	Buy	1.91	13,123	24,999	16,268	Apr 28 06:46 PM
McClung David	Chief Financial Officer	Apr 23 '25	Buy	1.91	13,123	24,999	43,131	Apr 25 09:38 PM
Facteau Bill	Director	Apr 23 '25	Buy	1.91	13,123	24,999	13,123	Apr 25 09:37 PM
Blank Andrew Scott	Director	Apr 23 '25	Buy	1.91	131,233	249,999	265,957	Apr 25 09:36 PM
STERTZER SIMON H	Director	Apr 23 '25	Buy	1.91	104,986	199,998	120,365	Apr 25 09:35 PM
Altman Peter	President and CEO	Apr 23 '25	Buy	1.91	26,246	49,999	138,966	Apr 25 09:35 PM
Altman Peter	President and CEO	Apr 15 '25	Buy	2.14	100	214	112,720	Apr 17 07:44 PM
Altman Peter	President and CEO	Apr 11 '25	Buy	2.03	300	609	112,620	Apr 14 07:41 PM
Altman Peter	President and CEO	Apr 10 '25	Buy	1.99	300	597	112,320	Apr 14 07:41 PM
Altman Peter	President and CEO	Apr 07 '25	Buy	1.96	500	980	112,020	Apr 08 05:01 PM
Altman Peter	President and CEO	Apr 04 '25	Buy	2.04	800	1,632	111,520	Apr 07 05:10 PM
Altman Peter	President and CEO	Apr 03 '25	Buy	2.20	600	1,320	110,720	Apr 04 05:04 PM
Altman Peter	President and CEO	Apr 02 '25	Buy	2.23	500	1,115	110,120	Apr 04 05:04 PM
Altman Peter	President and CEO	Apr 03 '25	Buy	2.24	1,200	2,688	109,620	Apr 03 09:08 PM
STERTZER SIMON H	Director	Mar 05 '25	Buy	2.45	1,000	2,450	57,138	Mar 07 08:30 AM
STERTZER SIMON H	Director	Mar 03 '25	Buy	2.30	22,753	52,332	40,602	Mar 05 08:30 AM
STERTZER SIMON H	Director	Mar 04 '25	Buy	2.30	15,536	35,733	56,138	Mar 05 08:30 AM
Altman Peter	President and CEO	Mar 03 '25	Buy	2.11	500	1,055	108,420	Mar 04 08:30 AM
Altman Peter	President and CEO	Feb 07 '25	Buy	2.48	600	1,488	107,920	Feb 11 05:42 PM
Altman Peter	President and CEO	Jan 29 '25	Buy	2.40	500	1,200	107,081	Jan 30 08:36 PM
Altman Peter	President and CEO	Jan 30 '25	Buy	2.38	239	569	107,320	Jan 30 08:36 PM
Altman Peter	President and CEO	Dec 23 '24	Buy	2.06	1,000	2,060	106,581	Dec 26 02:30 PM
GILLIS EDWARD M	Senior Vice President, Devices	Dec 20 '24	Sale	2.00	3,257	6,514	8,968	Dec 26 02:30 PM
GILLIS EDWARD M	Officer	Dec 17 '24	Proposed Sale	2.03	3,257	6,611		Dec 17 11:50 AM
Altman Peter	President and CEO	Dec 05 '24	Buy	2.22	250	555	105,581	Dec 09 05:04 PM
Altman Peter	President and CEO	Nov 15 '24	Buy	1.87	1,350	2,524	105,331	Nov 19 08:00 AM
Altman Peter	President and CEO	Jul 01 '24	Buy	3.05	300	915	39,745	Jul 02 04:12 PM
Altman Peter	President and CEO	Jun 28 '24	Buy	2.99	200	598	39,445	Jul 02 04:12 PM
Altman Peter	President and CEO	Jun 21 '24	Buy	3.29	500	1,645	39,245	Jun 24 08:46 AM
Altman Peter	President and CEO	Jun 14 '24	Buy	3.52	500	1,760	38,745	Jun 17 07:00 AM
Altman Peter	President and CEO	Jun 10 '24	Buy	3.36	1,000	3,360	38,245	Jun 12 07:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BCDA

BioCardia Inc

Upgrade your FINVIZ experience